SkinBioTherapeutics PLC Holding(s) in Company
12 Dicembre 2024 - 3:45PM
RNS Regulatory News
RNS Number : 9122P
SkinBioTherapeutics PLC
12 December 2024
TR-1: Standard form for notification of major
holdings
NOTIFICATION OF
MAJOR HOLDINGS(to be sent to the relevant issuer
and to the FCA in Microsoft Word format if
possible)
|
|
1a. Identity of the
issuer or the underlying issuer of existing shares to which voting
rights are attached:
|
SkinBioTherapeutics
plc
Company No: 09632164
(England)
|
1b. Please indicate
if the issuer is a non-UK issuer(please mark with an "X" if
appropriate)
|
Non-UK issuer
|
|
2. Reason for the
notification(please mark the appropriate box or boxes with
an "X")
|
An acquisition or disposal of voting
rights
|
X
|
An acquisition or disposal of
financial instruments
|
|
An event changing the breakdown of
voting rights
|
|
Other (please specify):
|
|
3. Details of person
subject to the notification obligation
|
Name
|
Optibiotix Health PLC
|
City and country of registered
office (if applicable)
|
York (UK)
|
4. Full name of
shareholder(s)(if different from 3.)
|
Name
|
|
City and country of registered
office (if applicable)
|
|
5. Date on which the
threshold was crossed or reached:
|
10 December 2024
|
6. Date on which
issuer notified (DD/MM/YYYY):
|
12 December 2024
|
7. Total positions
of person(s) subject to the notification obligation
|
|
% of
voting rights attached to shares (total of 8. A)
|
% of
voting rights through financial instruments
(total of
8.B 1 + 8.B 2)
|
Total of both in % (8.A +
8.B)
|
Total number of voting rights held
in issuer (8.A + 8.B) vii
|
Resulting situation on the date on
which threshold was crossed or reached
|
9.58%
|
|
9.58%
|
21,884,389
|
|
|
|
|
|
| |
Position of previous notification
(if applicable)
|
10.92%
|
|
10.92%
|
24,940,639
|
8. Notified details
of the resulting situation on the date on which the threshold was
crossed or reached
|
A: Voting rights
attached to shares
|
Class/type of shares
ISIN code (if possible)
|
Number of voting rights
|
%
of voting rights
|
Direct
(DTR5.1)
|
Indirect
(DTR5.2.1)
|
Direct
(DTR5.1)
|
Indirect
(DTR5.2.1)
|
Ordinary
|
21,884,389
|
|
9.58%
|
|
|
|
|
|
|
|
|
|
|
|
SUBTOTAL 8. A
|
21,884,389
|
9.58%
|
|
B 1: Financial
Instruments according to DTR5.3.1R (1) (a)
|
Type of financial instrument
|
Expiration date
x
|
Exercise/ Conversion
Period xi
|
Number of voting rights that may be acquired if the instrument
is exercised/converted.
|
% of voting rights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SUBTOTAL 8. B 1
|
|
|
|
B 2: Financial
Instruments with similar economic effect according to DTR5.3.1R (1)
(b)
|
Type of financial
instrument
|
Expiration date
x
|
Exercise/ Conversion Period
xi
|
Physical or cash
Settlement xii
|
Number of voting rights
|
% of voting rights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
9. Information in
relation to the person subject to the notification
obligation (please mark the applicable box with an "X")
|
Person subject to the notification
obligation is not controlled by any natural person or legal entity
and does not control any other undertaking(s) holding directly or
indirectly an interest in the (underlying) issuer
xiii
|
X
|
Full chain
of controlled undertakings through which the voting rights and/or
the
financial instruments are
effectively held starting with the ultimate controlling natural
person or legal entity (please add additional rows as
necessary) xiv
|
|
Name
|
% of voting rights if it equals or is higher
than the notifiable threshold
|
% of voting rights through financial
instruments if it equals or is higher than the notifiable
threshold
|
Total of both if it equals or is higher than
the notifiable threshold
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.
In case of proxy
voting, please identify:
|
Name of the proxy holder
|
|
The number and % of voting rights held
|
|
The date until which the voting rights will be
held
|
|
|
11. Additional
information
|
|
|
|
|
| |
Place of
completion
|
London
|
Date of completion
|
11 December 2024
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
HOLTTBITMTIBBTI
Grafico Azioni Skinbiotherapeutics (LSE:SBTX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Skinbiotherapeutics (LSE:SBTX)
Storico
Da Dic 2023 a Dic 2024